To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds

NCT ID: NCT04224649

Last Updated: 2020-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-23

Study Completion Date

2020-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Investigational Device : HARA (Hyaluronic Acid Filler)
* Title : A Single center, Randomized, Subject \& Evaluator-blind, Matched pairs, Active-controlled design Pivotal study to Evaluate the Efficacy and Safety of Injection with HARA as Compared to Restylane® Lidocaine in temporary Correction of Nasolabial folds
* Sites and investigators : Chung-ang University Hospital(Seoul), Beom-Joon Kim, M.D, Ph.D
* Objective : To compare the non-inferiority of HARA with Restylane® Lidocaine for evaluation of the efficacy and safety on Nasolabial Folds

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasolabial FOLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Device Group(HARA filler)

Group Type EXPERIMENTAL

HARA Filler(Hyaluronic acid Filler)

Intervention Type DEVICE

The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Comparator Group(Restylane® Lidocaine)

Group Type ACTIVE_COMPARATOR

Restylane® Lidocaine

Intervention Type DEVICE

The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HARA Filler(Hyaluronic acid Filler)

The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Intervention Type DEVICE

Restylane® Lidocaine

The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Those who agreed to this treatment and signed the Informed Consent Form
2. Those who are 19 years old or more and desire to take correction of nasolabial folds
3. Those who have an intention of refraining from other cosmetic treatment(other filler injection, laser or chemical peeling, Botox injection or wrinkle reduction) during the clinical study period
4. Those whose Wrinkle Severity Rating Scale (WSRS) is more than 2 points at least

Exclusion Criteria

1. Those who are sensitive to lidocaine or other amide anesthesia
2. Those who are sensitive to control device
3. Those who are pregnant or lactating, or expect pregnancy
4. Those who are judged by the subinvestigator to be improper for this study
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Humedix Co., Ltd.

INDUSTRY

Sponsor Role collaborator

Huons Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Huons

Seongnam-si, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Choi Yubeen

Role: primary

07074925965

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HU-055

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RHA® 4 NLF Cannula
NCT04754646 COMPLETED NA